Spravato Treatment

SPRAVATO® is the first nasal spray medication specifically for adults with treatment-resistant depression (TRD).

WHAT IS SPRAVATO

SPRAVATO® is a breakthrough treatment for major depressive disorder. It is an intranasal prescription medicine, used along with an antidepressant taken by mouth, for treatment-resistant depression (TRD) in adults. TRD is defined as the failure of two or more oral antidepressants of adequate dose and duration to produce a response or remission.

If you’ve struggled with depression and tried two or more antidepressants in your current episode without adequate relief, schedule an evaluation with us to see if SPRAVATO may benefit you.

Advantages of SPRAVATO

Medical professionals recommend SPRAVATO™ for patients who tried and did not respond to two or more antidepressants. SPRAVATO™ treatment offers these benefits:

Alternative to ketamine infusion: IV Ketamine infusions have been shown in multiple large randomized controlled clinical trials to be safe and effective as a treatment for depression. However, some patients prefer not to have an IV infusion. Spravato provides an alternative, FDA approved ketamine based treatment for depression.
Medical supervision: During your SPRAVATO™ treatment regimen, your doctor will work closely with you to ensure your well-being. You will receive each dosage at the office.
New option for treatment-resistant depression: SPRAVATO™ is one of the first new types of depression medication in decades. If you don’t have success with other depression medicines, SPRAVATO™ may be an alternative for you.

What to Expect During Your SPRAVATO® Treatment

Watch this video to learn about the SPRAVATO® treatment process.

SPRAVATO™ is a prescription medicine, used along with an antidepressant taken by mouth, for treatment-resistant depression (TRD) in adults.

SPRAVATO™ is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO™ is safe or effective as an anesthetic medicine

SPRAVATO™ nasal spray was evaluated for safety in both short- and long-term clinical trials of adults diagnosed with treatment-resistant depression.

Do not take SPRAVATO™ if you have a blood vessel disease (aneurysm), an abnormal connection between your blood vessels (arteriovenous malformation), a history of bleeding in the brain or are allergic to esketamine, ketamine or any of the ingredients in SPRAVATO™.

How Effective Is SPRAVATO™?

To get FDA approval, SPRAVATO™ underwent three short clinical trials and one longer trial. During the short-term trials, participants were either given SPRAVATO™ or a nasal spray placebo. Whether they received esketamine or the placebo, all trial participants were also given an antidepressant. They continued on the antidepressant throughout the trial.

In one trial, patients who received SPRAVATO™ nasal spray had statistically significant results compared to those who took the placebo. During the long-term trial, patients who had a stable response or who were in remission but continued treatment with SPRAVATO™ and an antidepressant had longer periods between symptom relapses compared to participants who received the placebo.

Upon approval of SPRAVATO™ (esketamine), Janssen, the company that produces it, issued a press release that stated that the medication could help reduce symptoms of depression within 24 hours when used with an oral antidepressant. Some patients in the clinical trial saw an improvement of their symptoms within four hours.

Connections Wellness Denton

Connections Wellness Frisco

Maxhealth Colleyville

Monday - Friday

(888)990-0663